Literature DB >> 24085318

Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure.

Yu-long Luo1, Pei-bo Li, Chen-chen Zhang, Yan-fang Zheng, Sheng Wang, Yi-chu Nie, Ke-jian Zhang, Wei-wei Su.   

Abstract

OBJECTIVE: The effects of four antitussives, including codeine phosphate (CP), moguisteine, levodropropizine (LVDP) and naringin, on airway neurogenic inflammation and enhanced cough were investigated in guinea pig model of chronic cough.
METHODS: Guinea pigs were exposed to CS for 8 weeks. At the 7th and 8th week, the animals were treated with vehicle, CP (4.8 mg/kg), moguisteine (24 mg/kg), LVDP (14 mg/kg) and naringin (18.4 mg/kg) respectively. Then the cough and the time-enhanced pause area under the curve (Penh-AUC) during capsaicin challenge were recorded. The substance P (SP) content, NK-1 receptor expression and neutral endopeptidase (NEP) activity in lung were determined.
RESULTS: Chronic CS exposure induced a bi-phase time course of cough responsiveness to capsaicin. Eight weeks of CS exposure significantly enhanced the airway neurogenic inflammation and cough response in guinea pigs. Two weeks of treatment with CP, moguisteine, LVDP or naringin effectively attenuated the chronic CS-exposure enhanced cough. Only naringin exerted significant effect on inhibiting Penh-AUC, SP content and NK-1 receptor expression, as well as preventing the declining of NEP activity in lung.
CONCLUSIONS: Chronic CS-exposed guinea pig is suitable for studying chronic pathological cough, in which naringin is effective on inhibiting both airway neurogenic inflammation and enhanced cough.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085318     DOI: 10.1007/s00011-013-0664-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  39 in total

1.  Antitussive effect of naringin on experimentally induced cough in Guinea pigs.

Authors:  Sen Gao; Peibo Li; Hongliang Yang; Siqi Fang; Weiwei Su
Journal:  Planta Med       Date:  2010-07-19       Impact factor: 3.352

2.  Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure.

Authors:  Andrew Churg; Steven Zhou; Olena Preobrazhenska; Hsin Tai; Rona Wang; Joanne L Wright
Journal:  Am J Respir Cell Mol Biol       Date:  2008-08-21       Impact factor: 6.914

3.  Sidestream smoke exposure enhances rapidly adapting receptor responses to substance P in young guinea pigs.

Authors:  A C Bonham; K S Kott; J P Joad
Journal:  J Appl Physiol (1985)       Date:  1996-10

4.  Time course of cigarette smoke-induced pulmonary inflammation in mice.

Authors:  A I D'hulst; K Y Vermaelen; G G Brusselle; G F Joos; R A Pauwels
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

5.  Effectiveness of levodropropizine against cigarette smoke-induced airway hyperreactivity: possible mechanism.

Authors:  L Daffonchio; A Hernandez; G Melillo; G Clavenna; C Omini
Journal:  Eur J Pharmacol       Date:  1993-04-01       Impact factor: 4.432

6.  Substance P (NK1)- and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases.

Authors:  T R Bai; D Zhou; T Weir; B Walker; R Hegele; S Hayashi; K McKay; G P Bondy; T Fong
Journal:  Am J Physiol       Date:  1995-09

Review 7.  Extending the understanding of sensory neuropeptides.

Authors:  Katelijne O De Swert; Guy F Joos
Journal:  Eur J Pharmacol       Date:  2006-02-07       Impact factor: 4.432

8.  Passive smoke effects on cough and airways in young guinea pigs: role of brainstem substance P.

Authors:  Jesse P Joad; Paul A Munch; John M Bric; Samuel J Evans; Kent E Pinkerton; Chao-Yin Chen; Ann C Bonham
Journal:  Am J Respir Crit Care Med       Date:  2003-11-25       Impact factor: 21.405

Review 9.  Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines.

Authors:  Sidney S Braman
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

10.  Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs.

Authors:  Kazuo Takahama; Tetsuya Shirasaki
Journal:  Cough       Date:  2007-07-09
View more
  6 in total

1.  Association of cough hypersensitivity with tracheal TRPV1 activation and neurogenic inflammation in a novel guinea pig model of citric acid-induced chronic cough.

Authors:  Xianghuai Xu; Qiang Chen; Zhongmin Qiu; Cuiqin Shi; Hongmei Ding; Lan Wang; Hanjing Lv; Li Yu
Journal:  J Int Med Res       Date:  2018-06-07       Impact factor: 1.671

2.  Simultaneously Quantitative Analysis of Naringin and Its Major Human Gut Microbial Metabolites Naringenin and 3-(4'-Hydroxyphenyl) Propanoic Acid via Stable Isotope Deuterium-Labeling Coupled with RRLC-MS/MS Method.

Authors:  Taobin Chen; Hao Wu; Yan He; Wenjun Pan; Zenghao Yan; Yan Liao; Wei Peng; Li Gan; Yaohui Zhang; Weiwei Su; Hongliang Yao
Journal:  Molecules       Date:  2019-11-25       Impact factor: 4.411

Review 3.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

Review 4.  Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology.

Authors:  Zhen Chen; Pan Chen; Hao Wu; Rui Shi; Weiwei Su; Yonggang Wang; Peibo Li
Journal:  Biomolecules       Date:  2020-12-08

5.  Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species.

Authors:  Yang Bai; Wei Peng; Cuiping Yang; Wei Zou; Menghua Liu; Hao Wu; Loudi Fan; Peibo Li; Xuan Zeng; Weiwei Su
Journal:  Front Pharmacol       Date:  2020-03-27       Impact factor: 5.810

6.  Effect of Qinbai Qingfei Concentrated Pellets on substance P and neutral endopeptidase of rats with post-infectious cough.

Authors:  Weigang Jia; Wei Wang; Rui Li; Quanyu Zhou; Ying Qu; Yumei Jia; Zhiheng Zhang; Chengwei Wan; Wanwan Zhang
Journal:  BMC Complement Med Ther       Date:  2020-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.